Genomind

Genomind’s PGx test analyzes DNA and identifies prescription and over-the-counter medications better suited to the individual.

GenMedPro is a genetics-based medication management platform for prescribers, pharmacists, and care teams to quickly evaluate medication therapy regimens.

MentalHealthMap helps users explore what makes them unique.

Genomind’s pharmacogenetic testing provides genetic insights to help guide medication choices and personalized dosing, with reports for clinical treatment planning.

Depression and anxiety are common mental illnesses that often occur together. The page discusses differences and similarities between the conditions.

Genetics-Based Medication Management

Genomind’s Professional PGx Express and Mental Health Map are genetic tests presented as part of Mental Health 360.

Psychiatrists and psychologists provide specialized treatment for mental health conditions. The page compares them with other clinicians.

Genomind awarded DoD contract to advance pharmacogenomics, embedding genetic insights into military health records to improve care and readiness.

Evexia Diagnostics partners with Genomind to offer pharmacogenetic testing, enhancing personalized care and treatment outcomes.

Genomind announced an HLA-A test innovation for its comprehensive mental health pharmacogenetics (PGx) test.

Genomind announced the assignment of a Z-code for its mental health pharmacogenomic (PGx) testing.

Genomind identifies Dan Dowd as its Chief Clinical Officer and says he is committed to improving patient care.

Our Leadership Team Guiding our mission to bring innovation to precision medicine. Executive Leadership Team Maintaining our commitment to delivering compassionate care and innovative precision health technology solutions. Bill BrownChief Executive OfficerFor almost 35 years, Bill has proven his expertise in turbo charging companies. He focuses on accelerating growth and mastering successful exits. Daniel Dowd,

Genomind’s support team provides assistance with questions and information about its services.

Genomind empowers patients and providers with prescribing recommendations and genetic insights to improve health and well-being.

Genomind’s privacy policy, effective March 1, 2022, summarizes its data-handling practices and says identifiable data is not shared without consent, subject to an exception.

Genomind’s terms and conditions cover its website and related information, software, portals, products, communications, and services, subject to users’ acceptance of the terms, policies, and notices.